4 Small Biotechs That Could Give Gilead, Merck & Co. Pfizer Some Competition With NASH

Non­Alcoholic Steatohepatitis (NASH), often called a "silent epidemic" that is slowly destroying the livers tens of millions of Americans, has attracted the attention of over a dozen pharmaceutical companies, including Gilead, Merck and Pfizer. The NASH treatment race started a couple of years ago and has recently heated back up on news that Allergan Plc is buying three companies focused on liver disease, including Tobira Therapeutics (TBRA) for a combined $2.4 billion. But, investors may also want to consider a few other companies that have a chance to be the best solution for treating NASH.